PMID- 33530214
OWN - NLM
STAT- MEDLINE
DCOM- 20210210
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 4
DP  - 2021 Jan 29
TI  - Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with 
      autoimmune features.
PG  - e24260
LID - 10.1097/MD.0000000000024260 [doi]
LID - e24260
AB  - Interstitial pneumonia with autoimmune features (IPAF) is a special subtype of 
      interstitial lung disease that has received worldwide attention. Krebs von den 
      Lungen-6 (KL-6) and surfactant protein-A (SP-A) can be used as an important 
      biomarker of interstitial lung disease, but its exact relationship with IPAF is 
      poorly understood.A total of 65 IPAF patients were included in the study and were 
      followed up for 52 weeks. The KL-6 and SP-A were evaluated by chemiluminescence 
      enzyme immunoassay. The above indicators were tested at 2 time points, baseline 
      (the first admission of patients) and 52 weeks. We also collected the indicators 
      of antinuclear antibodies and rheumatoid factor. Based on high-resolution 
      computed tomography evaluations, patients were divided into: aggravation, stable, 
      and improvement group. At same time, 30 age-matched normal people as normal 
      control were recruited, the same information was collected. Correlations among 
      the groups were compared and analyzed.The KL-6 and SP-A level in IPAF patients 
      were significantly higher than normal controls (fold increase = 11.35 and 1.39, 
      both P < .001) and differed significantly at baseline and 52 weeks in IPAF 
      (difference ratio = 37.7% and 21.3%, P < .05, both). There were significant 
      differences at baseline and 52 weeks (r values of aggravation, improvement, and 
      stable groups for KL-6 were 0.705, 0.770, and 0.344, P = .001, .001, and .163, 
      and for SP-A the r value were 0.672, 0.375, and 0.316, P = .001, .126, and .152). 
      In aggravation group, KL-6 and SP-A were correlated with CT scores (both 
      P < .05). Diffusing capacity of the lung for carbon monoxide (DLCO) and forced 
      vital capacity (FVC), % predicted showed a progressive downward trend, with a 
      significant difference at baseline and 52 weeks in IPAF patients (difference 
      ratio = 23.8% and 20.6%, both P < .05). There was a significant correlation 
      between KL-6 and FVC % predicted and DLCO (both P < .05), SP-A showed negatively 
      correlated with DLCO, but not significantly correlated with FVC % predicted 
      (P < .05 and .47).This study demonstrated that KL-6 and SP-A can reflect disease 
      progression, and both 2 play a key role at reflection of lung epithelial cell 
      injury and fibrosis degree in IPAF.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Xue, Mingshan
AU  - Xue M
AD  - Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory 
      Health, State Key Laboratory of Respiratory Disease, National Clinical Research 
      Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou.
FAU - Cai, Chuanxu
AU  - Cai C
AD  - Department of Laboratory Medicine, Shenzhen Institute of Respiratory Diseases, 
      Shenzhen People's Hospital, First Affiliated Hospital of Southern University of 
      Science and Technology, Second Clinical Medical College of Jinan University, 
      Shenzhen, China.
FAU - Zeng, Yifeng
AU  - Zeng Y
AD  - Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory 
      Health, State Key Laboratory of Respiratory Disease, National Clinical Research 
      Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou.
FAU - Xu, Yifan
AU  - Xu Y
AD  - Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory 
      Health, State Key Laboratory of Respiratory Disease, National Clinical Research 
      Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou.
FAU - Chen, Huai
AU  - Chen H
AD  - Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory 
      Health, State Key Laboratory of Respiratory Disease, National Clinical Research 
      Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou.
FAU - Hu, Haisheng
AU  - Hu H
AD  - Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory 
      Health, State Key Laboratory of Respiratory Disease, National Clinical Research 
      Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou.
FAU - Zhou, Luqian
AU  - Zhou L
AD  - Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory 
      Health, State Key Laboratory of Respiratory Disease, National Clinical Research 
      Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou.
FAU - Sun, Baoqing
AU  - Sun B
AUID- ORCID: 0000-0002-1671-0723
AD  - Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory 
      Health, State Key Laboratory of Respiratory Disease, National Clinical Research 
      Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou.
LA  - eng
GR  - 81700096; 8196010329; 81871736/Chinese National Natural Science Foundation/
GR  - 20192048/Bureau of traditional Chinese Medicine Scientific Research Project of 
      Guangdong/
GR  - 201804020043/Science and Technology Innovation Committee Project of Guangzhou/
GR  - 201831802/Key projects of Guangzhou Education Bureau/
GR  - SKLRD-OP-201803, SKLRD-OP-201809/Open Project of State Key Laboratory of 
      Respiratory Disease/
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Biomarkers)
RN  - 0 (MUC1 protein, human)
RN  - 0 (Mucin-1)
RN  - 0 (Pulmonary Surfactant-Associated Protein A)
RN  - 0 (SFTPA1 protein, human)
RN  - 9009-79-4 (Rheumatoid Factor)
SB  - IM
MH  - Adult
MH  - Antibodies, Antinuclear/blood
MH  - Biomarkers/blood
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Lung/immunology/pathology
MH  - Lung Diseases, Interstitial/*blood/immunology/pathology
MH  - Male
MH  - Middle Aged
MH  - Mucin-1/*blood
MH  - Pulmonary Surfactant-Associated Protein A/*blood
MH  - Rheumatoid Factor/blood
PMC - PMC7850699
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2021/02/04 06:00
MHDA- 2021/02/11 06:00
PMCR- 2021/01/29
CRDT- 2021/02/03 01:01
PHST- 2020/04/24 00:00 [received]
PHST- 2020/12/14 00:00 [accepted]
PHST- 2021/02/03 01:01 [entrez]
PHST- 2021/02/04 06:00 [pubmed]
PHST- 2021/02/11 06:00 [medline]
PHST- 2021/01/29 00:00 [pmc-release]
AID - 00005792-202101290-00064 [pii]
AID - MD-D-20-03048 [pii]
AID - 10.1097/MD.0000000000024260 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Jan 29;100(4):e24260. doi: 
      10.1097/MD.0000000000024260.